Literature DB >> 2344514

Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population.

K V Pedersen1, P Carlsson, E Varenhorst, O Löfman, K Berglund.   

Abstract

OBJECTIVE: To study the acceptability, costs, psychosocial consequences, and organisation of screening for carcinoma of the prostate.
DESIGN: A randomly selected population was personally invited for digital rectal examination by a urologist and a general practitioner. Further examinations were performed if induration was felt. Each man completed a questionnaire on his response to the examination.
SETTING: General practices in the area of Norrköping. PATIENTS: 1494 Men aged 50-69 randomly selected from a population of 9026. MAIN OUTCOME MEASURE: Prostates having a firm nodular consistency.
RESULTS: Carcinoma of the prostate was suspected in 45 of 1163 patients examined; in 10 by the general practitioners, in 10 by the urologists, and in 25 by both. Forty four men had a fine needle aspiration biopsy, and carcinomas were found in 13 cases. Of these, one had been suspected by the general practitioner, four by urologists, and eight by both. The cost for each man was 11.60 pounds, and the cost for each case of carcinoma detected and treated by potentially curative methods was 2477 pounds. Of the 13 men with carcinoma, 10 underwent radical prostatectomy and one radiotherapy. One man had advanced disease and was given endocrine treatment, another was not treated. Only 193 men felt distress during the initial examination. Of the 44 men who had an aspiration biopsy, 25 experienced anxiety.
CONCLUSIONS: Screening for carcinoma of the prostate by a urologist or a general practitioner using digital rectal examination is a cost effective method of early diagnosis. Whether such screening leads to prolonged survival, however, remains doubtful.

Entities:  

Mesh:

Year:  1990        PMID: 2344514      PMCID: PMC1662742          DOI: 10.1136/bmj.300.6731.1041

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  9 in total

1.  The reliability of clinical methods, data and judgments (second of two parts).

Authors:  L M Koran
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

2.  Comparison of the efficacy of digital rectal examination and transrectal ultrasonography in the diagnosis of prostatic cancer.

Authors:  G Vallancien; D Prapotnich; L Sibert; P M Lugagne; B Veillon; J M Brisset; J Andre-Bougaran
Journal:  Eur Urol       Date:  1989       Impact factor: 20.096

3.  Treatment of localized prostatic cancer. Radical prostatectomy versus placebo. A 15-year follow-up.

Authors:  P O Madsen; P H Graversen; T C Gasser; D K Corle
Journal:  Scand J Urol Nephrol Suppl       Date:  1988

4.  Prostatic carcinoma. An autopsy study.

Authors:  S Lundberg; T Berge
Journal:  Scand J Urol Nephrol       Date:  1970

5.  Screening for carcinoma of the prostate. Rectal examination, and enzymatic and radioimmunologic measurements of serum acid phosphatase compared.

Authors:  P Vihko; M Kontturi; O Lukkarinen; J Ervasti; R Vihko
Journal:  Cancer       Date:  1985-07-01       Impact factor: 6.860

6.  Bone marrow aspiration biopsy and bone scanning in the staging of prostatic cancer.

Authors:  E Varenhorst; G Alund; E Lindström; J C Månson
Journal:  Br J Urol       Date:  1983-10

7.  Prostate cancer: comparison of transrectal US and digital rectal examination for screening.

Authors:  F Lee; P J Littrup; S T Torp-Pedersen; C Mettlin; T A McHugh; J M Gray; G H Kumasaka; R D McLeary
Journal:  Radiology       Date:  1988-08       Impact factor: 11.105

8.  Age, and size and grade of tumour predict prognosis in incidentally diagnosed carcinoma of the prostate.

Authors:  C M Goodman; A Busuttil; G D Chisholm
Journal:  Br J Urol       Date:  1988-12

9.  Early detection of prostate cancer by routine screening.

Authors:  G W Chodak; H W Schoenberg
Journal:  JAMA       Date:  1984-12-21       Impact factor: 56.272

  9 in total
  12 in total

1.  Facilitating prevention in primary care.

Authors:  D Mant
Journal:  BMJ       Date:  1992-03-14

2.  Prostate mechanical imaging: a new method for prostate assessment.

Authors:  Robert E Weiss; Vladimir Egorov; Suren Ayrapetyan; Noune Sarvazyan; Armen Sarvazyan
Journal:  Urology       Date:  2008-03       Impact factor: 2.649

Review 3.  Periodic health examination, 1991 update: 3. Secondary prevention of prostate cancer. Canadian Task Force on the Periodic Health Examination.

Authors: 
Journal:  CMAJ       Date:  1991-09-01       Impact factor: 8.262

4.  Screening for carcinoma of the prostate.

Authors:  D Chadwick; D A Gillatt; J C Gingell; P H Abrams
Journal:  BMJ       Date:  1990-07-14

5.  In pursuit of the prostate.

Authors:  T Dixon
Journal:  Can Fam Physician       Date:  1992-10       Impact factor: 3.275

Review 6.  Radical prostatectomy and prostate cancer screening: the need for national audit and research.

Authors:  R R Hall
Journal:  Ann R Coll Surg Engl       Date:  1994-11       Impact factor: 1.891

Review 7.  Digital Rectal Examination for Prostate Cancer Screening in Primary Care: A Systematic Review and Meta-Analysis.

Authors:  Leen Naji; Harkanwal Randhawa; Zahra Sohani; Brittany Dennis; Deanna Lautenbach; Owen Kavanagh; Monica Bawor; Laura Banfield; Jason Profetto
Journal:  Ann Fam Med       Date:  2018-03       Impact factor: 5.166

8.  Screening for prostate cancer. How can patients give informed consent?

Authors:  K G Marshall
Journal:  Can Fam Physician       Date:  1993-11       Impact factor: 3.275

9.  The value of appropriate assessment prior to specialist referral in men with prostatic symptoms.

Authors:  M R Quinlan; B J O'Daly; M F O'Brien; S Gardner; G Lennon; D W Mulvin; D M Quinlan
Journal:  Ir J Med Sci       Date:  2009-04-15       Impact factor: 1.568

10.  A comparison of virtual touch tissue quantification and digital rectal examination for discrimination between prostate cancer and benign prostatic hyperplasia.

Authors:  Xiaozhi Zheng; Ping Ji; Hongwei Mao; Jianqun Hu
Journal:  Radiol Oncol       Date:  2011-07-20       Impact factor: 2.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.